Premium
Self‐Assembly Protein Nanogels for Safer Cancer Immunotherapy
Author(s) -
Purwada Alberto,
Tian Ye F.,
Huang Weishan,
Rohrbach Kathleen M.,
Deol Simrita,
August Avery,
Singh Ankur
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201501062
Subject(s) - cancer immunotherapy , immunotherapy , antigen , immune system , nanogel , limiting , safer , immunogenicity , toxicity , cancer research , medicine , immunology , materials science , nanotechnology , drug delivery , computer science , mechanical engineering , computer security , engineering
Soluble antigen‐based cancer vaccines have poor retention in tissues along with suboptimal antigen processing by dendritic cells. Multiple booster doses are often needed, leading to dose‐limiting systemic toxicity . A versatile, immunomodulatory, self‐assembly protein nanogel vaccine is reported that induces robust immune cell response at lower antigen doses than soluble antigens, an important step towards biomaterials‐based safer immunotherapy approaches.